Hiv pre-immunization and immunotherapy

Classifications


■ A61K39/21 Retroviridae, e.g. equine infectious anemia virus

View 37 more classifications

Landscapes

Health & Medical Sciences	Q
Life Sciences & Earth Sciences	Q

Show more ~



Patent Citations (153)

Publication number	Priority date	Publication date	Assignee	Title
Family To Family Citations				
US5668255A	1984-06-07	1997-09-16	Seragen, Inc.	Hybrid molecules having translocation region and cell- binding region
AU6014094A	1992-12-02	1994-06-22	Baylor College Of Medicine	Episomal vectors for gene therapy
WO1995002697A1	1993-07-13	1995-01-26	Rhone-Poulenc Rorer S.A.	Defective adenovirus vectors and use thereof in gene therapy

CA2265460A1	1996-09-11	1998-03-19	The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services	Aav4 vector and uses thereof
WO1999009139A1	1997-08-15	1999-02-25	Rubicon Laboratory, Inc.	Retrovirus and viral vectors
WO1999021979A1	1997-10-28	1999-05-06	Maxygen, Inc.	Human papillomavirus vectors
JP2002506652A	1998-03-20	2002-03-05	トラステイーズ・オブ・ザ・ユニバーシテイ・オ ブ・ペンシルベニア	Compositions and methods for helper-free production of recombinant adeno-associated virus
DK1115290T3	1998-10-01	2009-06-22	Univ Southern California	Retroviral gene delivery system and methods for its use
US6156514A	1998-12-03	2000-12-05	Sunol Molecular Corporation	Methods for making recombinant cells
US6410013B1	1999-01-25	2002-06-25	Musc Foundation For Research Development	Viral vectors for use in monitoring HIV drug resistance
WO2000072886A1	1999-05-26	2000-12-07	Dana-Farber Cancer Institute, Inc.	Episomally replicating lentiviral vectors
AU2001257611A1	2000-04-28	2001-11-12	Avigen, Inc.	Polynucleotides for use in recombinant adeno- associated virus virion production
AU2001261515A1	2000-05-12	2001-11-26	The Regents Of The University Of California	Treatment of human papillomavirus (hpv)-infected cells
WO2001091802A1	2000-05-30	2001-12-06	Baylor College Of Medicine	Chimeric viral vectors for gene therapy
NO314588B1 *	2000-09-04	2003-04-14	Bionor Immuno As	HIV peptides, antigens, vaccine composition, immunoassay test kits and a method for detecting antibodies induced by HIV
US7122181B2	2000-12-19	2006-10-17	Research Development Foundation	Lentiviral vector-mediated gene transfer and uses thereof
US20030119770A1	2001-08-02	2003-06-26	Zhennan Lai	Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors
WO2003015708A2	2001-08-18	2003-02-27	Myriad Genetics, Inc	Composition and method for treating hiv infection
US7737124B2	2001-09-13	2010-06-15	California Institute Of Technology	Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
WO2003040311A2	2001-10-25	2003-05-15	The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services	Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
US20070203333A1	2001-11-30	2007-08-30	Mcswiggen James	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)

CA2479530A1	2002-03-20	2003-10-02	Massachusetts Institute Of Technology	Hiv therapeutic
US20040142416A1	2002-04-30	2004-07-22	Laipis Philip J.	Treatment for phenylketonuria
W02004037847A2	2002-05-07	2004-05-06	Chiron Corporation	Hiv envelope-cd4 complexes and hybrids
US20040161412A1	2002-08-22	2004-08-19	The Cleveland Clinic Foundation	Cell-based VEGF delivery
DK1545204T3	2002-09-06	2016-11-14	The Government Of The Us Secretary Dept Of Health And Human Services	Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
JP2006505288A	2002-11-04	2006-02-16	ユニバーシティー オブ マサチューセッツ	Allele-specific RNA interference
AU2003283174A1	2002-12-11	2004-06-30	Cytos Biotechnology Ag	Method for protein production
TW200502391A	2003-05-08	2005-01-16	Xcyte Therapies Inc	Generation and isolation of antigen-specific t cells
W02004104591A2	2003-05-23	2004-12-02	Institut National De La Sante Et De La Recherche Medicale	Improvements to gamma delta t cell-mediated therapy
EP1644508A1	2003-07-11	2006-04-12	Cytos Biotechnology AG	Gene expression system
US20050019927A1	2003-07-13	2005-01-27	Markus Hildinger	DECREASING GENE EXPRESSION IN A MAMMALIAN SUBJECT IN VIVO VIA AAV-MEDIATED RNAI EXPRESSION CASSETTE TRANSFER
US20050138677A1	2003-09-16	2005-06-23	Pfister Herbert J.	Transgenic animal model for the treatment of skin tumors
W02005028634A2	2003-09-18	2005-03-31	Emory University	Improved mva vaccines
W02005033282A2	2003-10-01	2005-04-14	Pharmacia & Upjohn Company Llc	Polyamide compositions and therapeutic methods for treatment of human papilloma virus
US20080039413A1	2003-10-21	2008-02-14	Morris David W	Novel compositions and methods in cancer
JPW02005051927A1	2003-11-26	2007-12-06	株式会社クレハ	Method for culturing CD4-positive T cells by stimulation culture of HIV-1-infected peripheral blood mononuclear cells, and HIV-1 growth inhibitor
EP1753777B1	2004-02-25	2014-05-07	Dana-Farber Cancer Institute, Inc.	METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF HIV INFECTION USING TRIM5a
EP1737956A2	2004-03-01	2007-01-03	Massachusetts Institute of Technology	Rnai-based therapeutics for allergic rhinitis and asthma
TWI439284B	2004-04-09	2014-06-01	Abbvie Biotechnology Ltd	Multiple-variable dose regimen for treating $tnf\alpha$ -related disorders
US20080227736A1	2004-06-03	2008-09-18	Regents Of The University Of California,	Targeting Pseudotyped Retroviral Vectors

W02006039721A2 2004-08-16 2006-03-02 The Cbr institute For Biomedical Research, Inc. Method of delivering ma interference and uses thereof W02006039721A2 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Biophospherate compounds and methods for bone resignation of indicases, cancer by home plain, immune disease, cancer by production of replication of replicatio	W02006012221A2	2004-06-25	2006-02-02	The Regents Of The University Of California	Target cell-specific short interfering rna and methods of use thereof
EP1647595A1* 2004-10-15 2006-04-19 Academisch Medisch Centrum bij de Universiteit Nucleic acids against viruses, in particular HIV van Amsterdam W02006048215A1 2004-11-02 2006-05-11 Istituto Di Ricerche Di Biologia Molecolare P Adenoviral amplicon and producer cells for the production of replication-defective adenoviral vectors, methods of preparation and use thereof US779044682 2005-02-11 2010-09-07 Kosagen Cell Factory Oü Vectors, cell lines and their use in obtaining extended personal maintenance replication of rhybrid plasmids and expression of gene products CN101160055A 2005-02-16 2008-04-09 莱蒂尼公司 Lentiviral vectors and their use EP2573185A3 2005-02-16 2013-06-05 Lentigen Corporation Lentiviral vectors and their use EP2573185A3 2005-02-27 2016-03-21 Ospedale San Raffaele Srl Gene vector comprising miRNA W02007015122A1 2005-08-02 2007-02-08 Genexel, Inc. Therapy for alzheimer's disease W020070632443A1 2005-08-02 2007-02-08 Jaeseob Kim Therapy for Alzheimer's disease W02007056388A2 2005-11-07 2007-05-18 The General Hospital Corporation Compositions and methods for modulating poly (adpribase) polymerase activity W02007133674A2 2006-05-12 2007-11-22 Lentigen Corporation Lentiviral vector compositions, methods and applications US80389782 2006-05-12 2007-11-22 Lentigen Corporation Lentiviral vector compositions, methods and applications W02007063443A1 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cyclotoxicity (ADCC) and uses of T cells expressing CIVEN (ADCC) and uses of T cells expressing CIVEN (ADCC) and uses of T cells expressing of the efficiency of therapeutic antibodies using gamma delita cell activator compositions for increasing the efficiency of therapeutic antibodies using gamma delita cell activator compounds	WO2006023491A2	2004-08-16	2006-03-02	The Cbr Institute For Biomedical Research, Inc.	Method of delivering rna interference and uses thereof
W02006048215A1 204-11-02 206-05-11 Islituto Di Ricerche Di Biologia Molecolare P Adenoviral amplicon and producer cells for the production of replication-defective adenoviral vectors, methods of preparation and use thereof	WO2006039721A2	2004-10-08	2006-04-13	The Board Of Trustees Of The University Of Illinois	resorption diseases, cancer, bone pain, immune
Nageletti Spa	EP1647595A1 *	2004-10-15	2006-04-19		Nucleic acids against viruses, in particular HIV
CN101160055A 2005-02-16 2008-04-09 莱蒂恩公司 Lentiviral vectors and their use EP2573185A3 2005-02-16 2013-06-05 Lentigen Corporation Lentiviral vectors and their use DK2002003T3 2005-02-16 2013-06-05 Lentigen Corporation Lentiviral vectors and their use DK2002003T3 2005-08-27 2016-03-21 Ospedale San Raffaele Srl Gene vector comprising miRNA WO2007015122A1 2005-08-02 2007-02-08 Genexel, Inc. Therapy for alzheimer's disease US20070032443A1 2005-08-02 2007-02-08 Jaeseob Kim Therapy for Alzheimer's disease WO2007056388A2 2005-11-07 2007-05-18 The General Hospital Corporation Corpositions and methods for modulating poly (adpribose) polymerase activity WO2007133674A2 2006-05-12 2007-11-22 Lentigen Corporation Lentiviral vector compositions, methods and applications US8535897B2 2006-06-19 2013-09-17 The Trustees Of Columbia University In The City Of New York WO20080003225A1 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors WO2008008719A2 2006-07-13 2008-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds	WO2006048215A1	2004-11-02	2006-05-11		production of replication-defective adenoviral vectors,
EP2573185A3 2005-02-16 2013-06-05 Lentigen Corporation Lentiviral vectors and their use DK2002003T3 2005-05-27 2016-03-21 Ospedale San Raffaele Srl Gene vector comprising miRNA W02007015122A1 2005-08-02 2007-02-08 Genexel, Inc. Therapy for alzheimer's disease US20070032443A1 2005-08-02 2007-02-08 Jaeseob Kim Therapy for Alzheimer's disease W02007056388A2 2005-11-07 2007-05-18 The General Hospital Corporation Compositions and methods for modulating poly (adpribose) polymerase activity W02007133674A2 2006-05-12 2007-11-22 Lentigen Corporation Lentiviral vector compositions, methods and applications US8535897B2 2006-06-19 2013-09-17 The Trustees Of Columbia University In The City Of New York W020080003225A1 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing W02008008719A2 2006-07-10 2008-01-17 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the myc gene EP1878440A1 2006-07-13 2008-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds	US7790446B2	2005-02-11	2010-09-07	Kosagen Cell Factory Oü	episomal maintenance replication of hybrid plasmids
DK2002003T3 2005-05-27 2016-03-21 Ospedale San Raffaele Srl Gene vector comprising miRNA W02007015122A1 2005-08-02 2007-02-08 Genexel, Inc. Therapy for alzheimer's disease US20070032443A1 2005-08-02 2007-02-08 Jaeseob Kim Therapy for Alzheimer's disease W0200705638BA2 2005-11-07 2007-05-18 The General Hospital Corporation Compositions and methods for modulating poly (adpribose) polymerase activity W02007133674A2 2006-05-12 2007-11-22 Lentigen Corporation Lentiviral vector compositions, methods and applications US8535897B2 2006-06-19 2013-09-17 The Trustees Of Columbia University In The City Of New York W020080003225A1 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors W02008008719A2 2006-07-10 2008-01-17 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the myc gene EP1878440A1 2006-07-13 2008-01-16 INSERM (Institut National de la Santé et de la Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds	CN101160055A	2005-02-16	2008-04-09	莱蒂恩公司	Lentiviral vectors and their use
W02007015122A1 2005-08-02 2007-02-08 Genexel, Inc. Therapy for alzheimer's disease W020070032443A1 2005-08-02 2007-02-08 Jaeseob Kim Therapy for Alzheimer's disease W02007056388A2 2005-11-07 2007-05-18 The General Hospital Corporation Compositions and methods for modulating poly (adprilose) polymerase activity W02007133674A2 2006-05-12 2007-11-22 Lentigen Corporation Lentiviral vector compositions, methods and applications US8535897B2 2006-06-19 2013-09-17 The Trustees Of Columbia University In The City Of New York W020080003225A1 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors W02008008719A2 2006-07-10 2008-01-17 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the myc gene EP1878440A1 2006-07-13 2008-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds	EP2573185A3	2005-02-16	2013-06-05	Lentigen Corporation	Lentiviral vectors and their use
US20070032443A1 2005-08-02 2007-02-08 Jaeseob Kim Therapy for Alzheimer's disease WO2007056388A2 2005-11-07 2007-05-18 The General Hospital Corporation Compositions and methods for modulating poly (adpribose) polymerase activity WO2007133674A2 2006-05-12 2007-11-22 Lentigen Corporation Lentiviral vector compositions, methods and applications US8535897B2 2006-06-19 2013-09-17 The Trustees Of Columbia University In The City Of New York US20080003225A1 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors WO2008008719A2 2006-07-10 2008-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Method son compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds	DK2002003T3	2005-05-27	2016-03-21	Ospedale San Raffaele Srl	Gene vector comprising miRNA
W02007056388A2 2005-11-07 2007-05-18 The General Hospital Corporation Compositions and methods for modulating poly (adpribose) polymerase activity Compositions and methods for modulating poly (adpribose) polymerase activity Lentiviral vector compositions, methods and applications US8535897B2 2006-06-19 2013-09-17 The Trustees Of Columbia University In The City Of New York Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors W02008008719A2 2006-07-10 2008-01-17 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the myc gene Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds	WO2007015122A1	2005-08-02	2007-02-08	Genexel, Inc.	Therapy for alzheimer's disease
W02007133674A2 2006-05-12 2007-11-22 Lentigen Corporation Lentiviral vector compositions, methods and applications US8535897B2 2006-06-19 2013-09-17 The Trustees Of Columbia University In The City Of New York US20080003225A1 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors W02008008719A2 2006-07-10 2008-01-17 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the myc gene EP1878440A1 2006-07-13 2008-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds	US20070032443A1	2005-08-02	2007-02-08	Jaeseob Kim	Therapy for Alzheimer's disease
US8535897B2 2006-06-19 2013-09-17 The Trustees Of Columbia University In The City Of New York US20080003225A1 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors WO2008008719A2 2006-07-10 2008-01-17 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the myc gene EP1878440A1 2006-07-13 2008-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds	W02007056388A2	2005-11-07	2007-05-18	The General Hospital Corporation	
US20080003225A1 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors WO2008008719A2 2006-07-10 2008-01-17 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the myc gene EP1878440A1 2006-07-13 2008-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds	W02007133674A2	2006-05-12	2007-11-22	Lentigen Corporation	
W02008008719A2 2006-07-10 2008-01-17 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the myc gene EP1878440A1 2006-07-13 2008-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds	US8535897B2	2006-06-19	2013-09-17		Assays for non-apoptotic cell death and uses thereof
EP1878440A1 2006-07-13 2008-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds	US20080003225A1	2006-06-29	2008-01-03	Henri Vie	cytotoxicity (ADCC) and uses of T cells expressing
Recherche Médicale) efficiency of therapeutic antibodies using gamma delta cell activator compounds	W02008008719A2	2006-07-10	2008-01-17	Alnylam Pharmaceuticals, Inc.	
CN101516365A 2006-07-26 2009-08-26 诺瓦提斯公司 Inhibitors of undecaprenyl pyrophosphate synthase	EP1878440A1	2006-07-13	2008-01-16		efficiency of therapeutic antibodies using gamma
	CN101516365A	2006-07-26	2009-08-26	诺瓦提斯公司	Inhibitors of undecaprenyl pyrophosphate synthase

W02008100292A2 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods ES2639568T3* 2007-01-23 2017-10-27 Janssen Pharmaceutica Nv Method to design a drug regimen for HIV-infected patients CA2682694A1 2007-04-12 2008-10-23 The Board Of Trustees Of The University Of Illinois elihanced potency for multiple targets including ftps, agaps, and dpps US20080293142A1 2007-04-19 2008-11-27 The Board Of Regents For Oklahoma State University Multiple shRNA Expression Vectors and Methods of Controllinoin Controllino For Multiple shRNA Expression Vectors and Methods of Controllinoin State University US867347782 2008-06-16 2014-03-18 Perlop Deploys Battery Company High energy darry aqueous lithium/air-battery cells W02009025228A2* 2007-08-21 2009-02-26 Immune Disease Institute, Inc. Methods of delivery of agents to leukocytes and endothelial cells BRPI082199BA2 2008-01-16 2019-08-27 Opal Therapeutics Pty Ltd immune modulation compositions and uses thereof. EP2090659A1 2008-02-14 2008-03-26 Inst Superiore Di Santto Antisense RNA targetting CXCR4 EP2090659A1 2008-02-14 2009-08-19 Fraunhofer-G	US20080199961A1	2006-08-25	2008-08-21	Avi Biopharma, Inc.	ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF mIRNA BIOGENESIS
CA2682694A1 2007-04-12 2008-10-23 The Board Of Trustees Of The University Of Illinois Blaphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps US20080293142A1 2007-04-19 2008-11-27 The Board Of Regents For Oklahoma State Multiple shRNA Expression Vectors and Methods of Construction EP2008656A1 2007-06-28 2008-12-31 Bergen Teknologioverforing AS Compositions for the treatment of hyperphenylalaninemia US867347782 2008-06-16 2014-03-18 Polyplus Battery Company High energy density aqueous lithium/air-battery cells W02009026328A2* 2007-08-21 2009-02-26 Immune Disease Institute, Inc. Methods of delivery of agents to leukocytes and endothelial cells BRP10821998A2 2008-01-16 2019-08-27 Opal Therapeutics Pty Ltd immunomodulation compositions and uses thereof. GB0802754D0 2008-02-14 2008-03-26 Inst Superiore Di Sanito Antisense RNA targetting CXCRA EP2090659A1 2008-02-14 2009-08-19 Fraunhofer-Gesellschaft zur F\u00f6rderung der angewandten Forschung e.V. Infectious particle, process for its preparation and use thereof W02009120947A1 2008-03-28 2009-10-01 Virxsys Corporation Lentivirus-based immunogenic vectors GB081020900 2008-06-04 2008-07-09 Cambridge Entry Ltd Pluripotency associated epigenetic factor US8629334B2 2008-07-16 2014-01-14 University of Florida Research Foundation, Inc. Viral-based transient-expression vector system for trees W0201002195A2 2008-09-17 2018-04-11 Isogenis, Inc. Construction of fully idealeted adenovirus-based gene delivery vectors and uses thereof W02010045659A1 2008-10-31 2010-05-26 Lentigen Corporation Cell therapy product for the treatment of his infection US873479582 2008-10-31 2010-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof	WO2008100292A2	2006-10-16	2008-08-21	Genelux Corporation	
US20080293142A1 2007-04-19 2008-11-27 The Board Of Regents For Oklahoma State University Multiple shRNA Expression Vectors and Methods of Construction EP2008656A1 2007-06-28 2008-12-31 Bergen Teknologioverforing AS Compositions for the treatment of hyperphenylalaninemia US8673477B2 2008-06-16 2014-03-18 Polyplus Battery Company High energy density aqueous lithium/air-battery cells WC2009026328A2 * 2007-08-21 2009-02-26 Immune Disease Institute, Inc. Methods of delivery of agents to leukocytes and endothelial cells BRPI0821998A2 2008-01-16 2019-08-27 Opal Therapeutics Pty Ltd immunemodulation compositions and uses thereof. GB0802754D0 2008-02-14 2008-03-26 Inst Superiore Di Sanito Antisense RNA targetting CXCR4 EP2090659A1 2008-02-14 2009-08-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Infectious particle, process for its preparation and use thereof WC2009120947A1 2008-03-28 2009-10-01 Virxsys Corporation Lentivirus-based immunogenic vectors GB0810209D0 2008-06-04 2008-07-09 Cambridge Entpr Ltd Pluripotency associated epigenetic factor US8629334B2 2008-07-16 2014-01-14 University Of Florida Research Foundation, Inc. Viral-based transient-expression vector system for trees WC2010022195A2 2008-09-17 2018-04-11 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof WC2010045659A1 2008-09-31 2010-05-06 Lentigen Corporation Cell therapy product for the treatment of hiv infection US8734795B2 2008-10-31 2010-05-06 Lentigen Corporation Cell therapy product for the treatment of hiv infection	ES2639568T3 *	2007-01-23	2017-10-27	Janssen Pharmaceutica Nv	
EP2008656A1 2007-06-28 2008-12-31 Bergen Teknologioverforing AS Compositions for the treatment of hyperpherelylalsminemia US8673477B2 2008-06-16 2014-03-18 Polyplus Battery Company High energy density aqueous lithium/air-battery cells W02009026328A2 * 2007-08-21 2009-02-26 Immune Disease Institute, Inc. Methods of delivery of agents to leukocytes and endothelial cells BRPI0821998A2 2008-01-16 2019-08-27 Opal Therapeutics Pty Ltd immunomodulation compositions and uses thereof. GB0802754D0 2008-02-14 2008-03-26 Inst Superiore Di Sanito Antisense RNA targetting CXCR4 EP2090659A1 2008-02-14 2009-08-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Infectious particle, process for its preparation and use thereof W02009120947A1 2008-03-28 2009-10-01 Virxsys Corporation Lentivirus-based immunogenic vectors GB0810209D0 2008-06-04 2008-07-09 Cambridge Entpr Ltd Pluripotency associated epigenetic factor US8629334B2 2008-07-16 2014-01-14 University Of Florida Research Foundation, Inc. Viral-based transient-expression vector system for trees W02010022195A2 2008-08-20 2010-02-25 Virxsys Corporation Non-integrating lenti/adeno-associated virus hybrid vector system EP2342321B1 2008-09-17 2018-04-11 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof W02010045659A1 2008-10-31 2010-05-06 Lentigen Corporation Cell therape utic molecules W02010051521A1 2008-10-31 2010-05-06 Lentigen Corporation Cell therape product for the treatment of his infection US873479582 2008-10-31 2014-05-27 Biogen Idea Ma Inc.	CA2682694A1	2007-04-12	2008-10-23	The Board Of Trustees Of The University Of Illinois	enhanced potency for multiple targets including fpps,
US8673477B2 2008-06-16 2014-03-18 Polyplus Battery Company High energy density aqueous lithium/air-battery cells W02009026328A2 * 2007-08-21 2009-02-26 Immune Disease Institute, Inc. Methods of delivery of agents to leukocytes and endothelial cells BRPI0821998A2 2008-01-16 2019-08-27 Opal Therapeutics Pty Ltd immunomodulation compositions and uses thereof. GB0802754D0 2008-02-14 2008-03-26 Inst Superiore Di Sanito Antisense RNA targetting CXCR4 EP2090659A1 2008-02-14 2009-08-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Infectious particle, process for its preparation and use thereof W02009120947A1 2008-03-28 2009-10-01 Virxsys Corporation Lentivirus-based immunogenic vectors GB0810209D0 2008-06-04 2008-07-09 Cambridge Entpr Ltd Pluripotency associated epigenetic factor US8629334B2 2008-07-16 2014-01-14 University Of Florida Research Foundation, Inc. Viral-based transient-expression vector system for trees W02010022195A2 2008-08-20 2010-02-25 Virxsys Corporation Non-integrating lenti/adeno-associated virus hybrid vector system EP2342321B1 2008-09-17 2018-04-11 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof W02010045659A1 2008-10-31 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules W02010051521A1 2008-10-31 2010-05-06 Lentigen Corporation Cell therapy product for the treatment of hiv infection US8734795B2 2008-10-31 2014-05-27 Biogen Idea Ma Inc. Light targeting molecules and uses thereof	US20080293142A1	2007-04-19	2008-11-27		
W02009026328A2 * 2007-08-21 2009-02-26 Immune Disease Institute, Inc. Methods of delivery of agents to leukocytes and endothelial cells BRPI0821998A2 2008-01-16 2019-08-27 Opal Therapeutics Pty Ltd immunomodulation compositions and uses thereof. GB0802754D0 2008-02-14 2008-03-26 Inst Superiore Di Sanito Antisense RNA targetting CXCR4 EP2090659A1 2008-02-14 2009-08-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Infectious particle, process for its preparation and use thereof W02009120947A1 2008-03-28 2009-10-01 Virxsys Corporation Lentivirus-based immunogenic vectors GB0810209D0 2008-06-04 2008-07-09 Cambridge Entpr Ltd Pluripotency associated epigenetic factor US8629334B2 2008-07-16 2014-01-14 University Of Florida Research Foundation, Inc. Viral-based transient-expression vector system for trees W02010022195A2 2008-08-20 2010-02-25 Virxsys Corporation Non-integrating lenti/adeno-associated virus hybrid vector system EP2342321B1 2008-09-17 2018-04-11 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof W02010045659A1 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules W02010051521A1 2008-10-31 2010-05-06 Lentigen Corporation Cell therapy product for the treatment of hiv infection US8734795B2 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof	EP2008656A1	2007-06-28	2008-12-31	Bergen Teknologioverforing AS	
BRPI0821998A2 2008-01-16 2019-08-27 Opal Therapeutics Pty Ltd immunomodulation compositions and uses thereof. GB0802754D0 2008-02-14 2008-03-26 Inst Superiore Di Sanito Antisense RNA targetting CXCR4 EP2090659A1 2008-02-14 2009-08-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Infectious particle, process for its preparation and use thereof W02009120947A1 2008-03-28 2009-10-01 Virxsys Corporation Lentivirus-based immunogenic vectors GB0810209D0 2008-06-04 2008-07-09 Cambridge Entpr Ltd Pluripotency associated epigenetic factor US8629334B2 2008-07-16 2014-01-14 University Of Florida Research Foundation, Inc. Viral-based transient-expression vector system for trees W02010022195A2 2008-08-20 2010-02-25 Virxsys Corporation Non-integrating lenti/adeno-associated virus hybrid vector system EP2342321B1 2008-09-17 2018-04-11 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof W02010045659A1 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules W02010051521A1 2008-10-31 2010-05-06 Lentigen Corporation Cell therapy product for the treatment of hiv infection US8734795B2 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof	US8673477B2	2008-06-16	2014-03-18	Polyplus Battery Company	High energy density aqueous lithium/air-battery cells
GB0802754D0 2008-02-14 2008-03-26 Inst Superiore Di Sanito Antisense RNA targetting CXCR4 EP2090659A1 2008-02-14 2009-08-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Infectious particle, process for its preparation and use thereof W02009120947A1 2008-03-28 2009-10-01 Virxsys Corporation Lentivirus-based immunogenic vectors GB0810209D0 2008-06-04 2008-07-09 Cambridge Entpr Ltd Pluripotency associated epigenetic factor US8629334B2 2008-07-16 2014-01-14 University Of Florida Research Foundation, Inc. Viral-based transient-expression vector system for trees W02010022195A2 2008-08-20 2010-02-25 Virxsys Corporation Non-integrating lenti/adeno-associated virus hybrid vector system EP2342321B1 2008-09-17 2018-04-11 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof W02010045659A1 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules W02010051521A1 2008-10-31 2010-05-06 Lentigen Corporation Cell therapy product for the treatment of hiv infection US8734795B2 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof	WO2009026328A2 *	2007-08-21	2009-02-26	Immune Disease Institute, Inc.	
EP2090659A1 2008-02-14 2009-08-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Infectious particle, process for its preparation and use thereof W02009120947A1 2008-03-28 2009-10-01 Virxsys Corporation Lentivirus-based immunogenic vectors GB0810209D0 2008-06-04 2008-07-09 Cambridge Entpr Ltd Pluripotency associated epigenetic factor US8629334B2 2008-07-16 2014-01-14 University Of Florida Research Foundation, Inc. Viral-based transient-expression vector system for trees W02010022195A2 2008-08-20 2010-02-25 Virxsys Corporation Non-integrating lenti/adeno-associated virus hybrid vector system EP2342321B1 2008-09-17 2018-04-11 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof W02010045659A1 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules W02010051521A1 2008-10-31 2010-05-06 Lentigen Corporation Cell therapy product for the treatment of hiv infection US8734795B2 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof	BRPI0821998A2	2008-01-16	2019-08-27	Opal Therapeutics Pty Ltd	immunomodulation compositions and uses thereof.
angewandten Forschung e.V. thereof W02009120947A1 2008-03-28 2009-10-01 Virxsys Corporation Lentivirus-based immunogenic vectors GB0810209D0 2008-06-04 2008-07-09 Cambridge Entpr Ltd Pluripotency associated epigenetic factor US8629334B2 2008-07-16 2014-01-14 University Of Florida Research Foundation, Inc. Viral-based transient-expression vector system for trees W02010022195A2 2008-08-20 2010-02-25 Virxsys Corporation Non-integrating lenti/adeno-associated virus hybrid vector system EP2342321B1 2008-09-17 2018-04-11 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof W02010045659A1 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules W02010051521A1 2008-10-31 2010-05-06 Lentigen Corporation Cell therapy product for the treatment of hiv infection US8734795B2 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof	GB0802754D0	2008-02-14	2008-03-26	Inst Superiore Di Sanito	Antisense RNA targetting CXCR4
GB0810209D0 2008-06-04 2008-07-09 Cambridge Entpr Ltd Pluripotency associated epigenetic factor US8629334B2 2008-07-16 2014-01-14 University Of Florida Research Foundation, Inc. Viral-based transient-expression vector system for trees W02010022195A2 2008-08-20 2010-02-25 Virxsys Corporation Non-integrating lenti/adeno-associated virus hybrid vector system EP2342321B1 2008-09-17 2018-04-11 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof W02010045659A1 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules W02010051521A1 2008-10-31 2010-05-06 Lentigen Corporation Cell therapy product for the treatment of hiv infection US8734795B2 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof	EP2090659A1	2008-02-14	2009-08-19		
US8629334B2 2008-07-16 2014-01-14 University Of Florida Research Foundation, Inc. W02010022195A2 2008-08-20 2010-02-25 Virxsys Corporation Non-integrating lenti/adeno-associated virus hybrid vector system EP2342321B1 2008-09-17 2018-04-11 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof W02010045659A1 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules W02010051521A1 2008-10-31 2010-05-06 Lentigen Corporation Cell therapy product for the treatment of hiv infection US8734795B2 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof	WO2009120947A1	2008-03-28	2009-10-01	Virxsys Corporation	Lentivirus-based immunogenic vectors
trees WO2010022195A2 2008-08-20 2010-02-25 Virxsys Corporation Non-integrating lenti/adeno-associated virus hybrid vector system EP2342321B1 2008-09-17 2018-04-11 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof WO2010045659A1 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules WO2010051521A1 2008-10-31 2010-05-06 Lentigen Corporation Cell therapy product for the treatment of hiv infection US8734795B2 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof	GB0810209D0	2008-06-04	2008-07-09	Cambridge Entpr Ltd	Pluripotency associated epigenetic factor
vector system EP2342321B1 2008-09-17 2018-04-11 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof W02010045659A1 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules W02010051521A1 2008-10-31 2010-05-06 Lentigen Corporation Cell therapy product for the treatment of hiv infection US8734795B2 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof	US8629334B2	2008-07-16	2014-01-14	University Of Florida Research Foundation, Inc.	
W02010045659A1 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules W02010051521A1 2008-10-31 2010-05-06 Lentigen Corporation Cell therapy product for the treatment of hiv infection US8734795B2 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof	WO2010022195A2	2008-08-20	2010-02-25	Virxsys Corporation	
W02010051521A1 2008-10-31 2010-05-06 Lentigen Corporation Cell therapy product for the treatment of hiv infection US8734795B2 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof	EP2342321B1	2008-09-17	2018-04-11	Isogenis, Inc.	
US8734795B2 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof	WO2010045659A1	2008-10-17	2010-04-22	American Gene Technologies International Inc.	
	WO2010051521A1	2008-10-31	2010-05-06	Lentigen Corporation	Cell therapy product for the treatment of hiv infection
W02011071476A2 2008-11-14 2011-06-16 Life Technologies Corporation Compositions and methods for engineering cells	US8734795B2	2008-10-31	2014-05-27	Biogen Idec Ma Inc.	Light targeting molecules and uses thereof
	W02011071476A2	2008-11-14	2011-06-16	Life Technologies Corporation	Compositions and methods for engineering cells

EP2191834A1	2008-11-26	2010-06-02	Centre National De La Recherche Scientifique (Cnrs)	Compositions and methods for treating retrovirus infections
WO2010117974A2	2009-04-09	2010-10-14	Stemcyte Inc.	Hiv-resistant stem cells and uses thereof
EP2419113B1	2009-04-13	2017-05-10	Apceth GmbH & Co. KG	Engineered mesenchymal stem cells and method of using same to treat tumors
EP2425001A4	2009-04-30	2012-11-14	Univ California	Combination anti-hiv vectors, targeting vectors, and methods of use
EP3329772B1	2009-07-15	2019-10-16	Calimmune, Inc.	Dual vector for inhibition of human immunodeficiency virus
SG178909A1	2009-10-08	2012-04-27	Bavarian Nordic As	Generation of a broad t-cell response in humans against hiv
US20120027725A1	2009-11-30	2012-02-02	Galvin Jeffrey A	Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules to treat liver cancer
CN101805750B	2009-12-29	2011-11-30	浙江大学	Construction and application of farnesyl pyrophosphoric acid synthetase RNA (Ribonucleic Acid) interference recombinant lentivirus vector
CN102782136A *	2010-02-18	2012-11-14	爱默蕾大学	Vectors expressing HIV antigens and GM-CSF and related methods for generating an immune response
W02011119942A1	2010-03-25	2011-09-29	Vistagen Therapeutics, Inc.	Induction of ips cells using transient episomal vectors
W02011133687A2	2010-04-20	2011-10-27	President And Fellows Of Harvard College	Methods and compositions for inhibition of beta2- adrenergic receptor degradation
LT2561078T	2010-04-23	2019-01-10	Cold Spring Harbor Laboratory	NOVEL STRUCTURALLY DESIGNED shRNAs
US20110293571A1	2010-05-28	2011-12-01	Oxford Biomedica (Uk) Ltd.	Method for vector delivery
W02012020757A1	2010-08-10	2012-02-16	タカラバイオ 株式会社	Production method for cell populations
US20130281493A1	2010-10-07	2013-10-24	The Trustees Of The University Of Columbia In The City Of New York	Method for Treating Cancer Harboring a p53 Mutation
WO2012061075A2	2010-10-25	2012-05-10	The Regents Of The University Of California	Hiv resistant and functional hematopoietic stem/progenitor cells and macrophages from induced pluripotent stem cells
WO2012115980A1	2011-02-22	2012-08-30	California Institute Of Technology	Delivery of proteins using adeno-associated virus (aav) vectors
JP2014511704A	2011-04-13	2014-05-19	イミュニカム・エイビイ	Method for priming T cells
US9226976B2	2011-04-21	2016-01-05	University Of Massachusetts	RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies

EP2782596A4	2011-11-22	2015-07-29	Philadelphia Children Hospital	Virus vectors for highly efficient transgene delivery
US9745631B2	2011-12-20	2017-08-29	Dana-Farber Cancer Institute, Inc.	Methods for diagnosing and treating oncogenic kras- associated cancer
BR112014019431A8	2012-02-07	2017-07-11	Global Bio Therapeutics Usa Inc	COMPARTMENTALIZED METHOD OF DELIVERY OF NUCLEIC ACID AND COMPOSITIONS AND USES THEREOF
WO2013174404A1	2012-05-23	2013-11-28	Ganymed Pharmaceuticals Ag	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
AU2013273483A1	2012-06-06	2014-12-11	Bionor Immuno As	Vaccine
W02014016817A2	2012-07-17	2014-01-30	Universite De Geneve	Nucleic acids for down-regulation of gene expression
CA2922005A1	2012-09-27	2014-04-03	Population Diagnostics, Inc.	Methods and compositions for screening and treating developmental disorders
JP6391582B2	2012-11-13	2018-09-19	コディアック バイオサイエンシズ インコーポレイ テッド	Methods for delivering therapeutic agents
CA2892448A1	2012-12-05	2014-06-12	Sangamo Biosciences, Inc.	Methods and compositions for regulation of metabolic disorders
US9642921B2	2012-12-20	2017-05-09	Tocagen Inc.	Cancer combination therapy and recombinant vectors
W02014117050A2	2013-01-26	2014-07-31	Mirimus, Inc.	Modified mirna as a scaffold for shrna
CN103184224A	2013-04-03	2013-07-03	衡阳师范学院	Triple minRNA for resisting virus infection of aids and construction method thereof
W02014187881A1	2013-05-21	2014-11-27	Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V.	Isoforms of gata6 and nkx2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
AU2014296059B2	2013-08-02	2020-12-10	The Regents Of The University Of California	Engineering antiviral T cell immunity through stem cells and chimeric antigen receptors
W02015042308A2	2013-09-18	2015-03-26	City Of Hope	Rna-based hiv inhibitors
AU2014340083B2	2013-10-22	2019-08-15	Translate Bio, Inc.	mRNA therapy for phenylketonuria
CN106459995B	2013-11-07	2020-02-21	爱迪塔斯医药有限公司	CRISPR-associated methods and compositions using dominant grnas
EP2878674A1	2013-11-28	2015-06-03	Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC)	Stable episomes based on non-integrative lentiviral vectors
GB201322091D0	2013-12-13	2014-01-29	Cambridge Entpr Ltd	Modified serpins for the treatment of bleeding disorders

CA2946312A1	2014-04-23	2015-10-29	Juno Therapeutics, Inc.	Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
DK3851537T3	2014-04-25	2024-03-18	Genethon	TREATMENT OF HYPERBILIRUBINAMIA
PL3689899T3	2014-04-25	2022-01-31	2Seventy Bio, Inc.	Mnd promoter chimeric antigen receptors
CA2955254A1	2014-08-29	2016-03-03	Immunomedics, Inc.	Identification of cancer genes by in-vivo fusion of human cancer cells and animal cells
SI3197472T1	2014-09-22	2022-01-31	Tanea Medical Ab	Recombinant phe-free proteins for use in the treatment of phenylketonuria
MA40783A *	2014-10-03	2017-08-08	Los Alamos Nat Security Llc	HIV VACCINES CONTAINING ONE OR MORE POPULATION EPISENSUS ANTIGENS
AU2015329696A1	2014-10-10	2017-04-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Methods to eliminate cancer stem cells by targeting CD47
CN107405357B	2014-10-14	2021-12-31	德克萨斯科技大学系统	Multiple shRNAs and application thereof
JP2017534284A *	2014-10-27	2017-11-24	インターナショナル エイズ バクシーン イニシアティブ	Genetically stable replicable Sendai virus vector containing and expressing an optimized HIV gene
WO2016069716A1	2014-10-30	2016-05-06	The Scripps Research Institute	Compositions and methods comprising tyrosyl-trna synthetases and resveratrol compounds
W02016186708A1	2015-05-18	2016-11-24	Calimmune, Inc.	Gene therapeutic for the treatment of hiv and uses thereof
GB201509202D0	2015-05-28	2015-07-15	Ge Healthcare Bio Sciences Ab	Semi-static cell culture
JP6924487B2	2015-06-10	2021-08-25	アメリカン ジーン テクノロジーズ インターナショ ナル インコーポレイテッド	Non-embedded virus delivery system and how to use it
W02017007994A1 *	2015-07-08	2017-01-12	American Gene Technologies International Inc.	Hiv pre-immunization and immunotherapy
JP6780870B2	2015-08-13	2020-11-04	北昊干細胞与再生医学研究院有限公司 Beiha o Stem Cell And Regenerat ive Medicine Research Ins titute Co., Ltd.	Induced expanded pluripotent stem cells, how to make and use
CN105112370B	2015-08-25	2019-02-05	杭州优善生物科技有限公司	A kind of method and its application of stimulated in vitro peripheral blood gamma delta T cells high efficiently multiplying
JP7059179B2	2015-10-20	2022-04-25	アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル	Methods and products for genetic engineering

US11389546B2	2015-12-09	2022-07-19	Modernatx, Inc.	Heterologous UTR sequences for enhanced mRNA expression
US10137144B2	2016-01-15	2018-11-27	American Gene Technologies International Inc.	Methods and compositions for the activation of gamma-delta T-cells
EP4310500A3	2016-01-15	2024-04-03	American Gene Technologies International Inc.	Methods and compositons for the activation of gamma-delta t-cells
EP3413926A4	2016-02-08	2019-10-09	American Gene Technologies International, Inc.	Hiv vaccination and immunotherapy
W02017156311A2	2016-03-09	2017-09-14	American Gene Technologies International Inc.	Combination vectors and methods for treating cancer
W02017173453A1	2016-04-01	2017-10-05	The Brigham And Women's Hospital, Inc.	Stimuli-responsive nanoparticles for biomedical applications
JP7173548B2	2016-06-08	2022-11-16	アメリカン ジーン テクノロジーズ インターナショ ナル インコーポレイテッド	Non-Integrating Viral Delivery Systems and Related Methods
AU2017292582C1	2016-07-08	2021-11-11	American Gene Technologies International Inc.	HIV pre-immunization and immunotherapy
EP3487507A4	2016-07-21	2020-04-08	American Gene Technologies International, Inc.	Viral vectors for treating parkinson's disease
WO2018025923A1	2016-08-03	2018-02-08	国立大学法人鹿児島大学	Anti-htlv-1 drug and therapeutic agent for htlv-1- associated myelopathy/tropical spastic paraparesis (ham/tsp)
KR20190100318A	2016-12-30	2019-08-28	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	Gene therapy to treat phenylketonuria
EP3565564A4	2017-01-09	2020-09-23	American Gene Technologies International Inc.	Hiv immunotherapy with no pre-immunization step
CN110621322A	2017-02-08	2019-12-27	达纳-法伯癌症研究所有限公司	Modulatable endogenous protein degradation with heterobifunctional compounds
US11820999B2	2017-04-03	2023-11-21	American Gene Technologies International Inc.	Compositions and methods for treating phenylketonuria
US20200181645A1	2017-06-16	2020-06-11	American Gene Technologies International Inc.	Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
CN111433368A	2017-10-02	2020-07-17	美国基因技术国际有限公司	Vector with promoter and enhancer combination for treating phenylketonuria
WO2020011247A1	2018-07-13	2020-01-16	Nanjing Legend Biotech Co., Ltd.	Co-receptor systems for treating infectious diseases
US11352646B2	2018-11-05	2022-06-07	American Gene Technologies International Inc.	Vector system for expressing regulatory RNA
KR20220068954A	2019-05-31	2022-05-26	아메리칸 진 테크놀로지스 인터내셔널 인코포레이 티드	Optimized phenylalanine hydroxylase expression
* Cited by examiner + Cited by third party				

^{*} Cited by examiner, † Cited by third party

Publication number	Priority date	Publication date	Assignee	Title
Family To Family Citations				
WO2010045659A1	2008-10-17	2010-04-22	American Gene Technologies International Inc.	Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
US10137144B2	2016-01-15	2018-11-27	American Gene Technologies International Inc.	Methods and compositions for the activation of gamma-delta T-cells
EP4310500A3	2016-01-15	2024-04-03	American Gene Technologies International Inc.	Methods and compositons for the activation of gamma-delta t-cells
EP3413926A4	2016-02-08	2019-10-09	American Gene Technologies International, Inc.	Hiv vaccination and immunotherapy
WO2017156311A2	2016-03-09	2017-09-14	American Gene Technologies International Inc.	Combination vectors and methods for treating cancer
AU2017292582C1	2016-07-08	2021-11-11	American Gene Technologies International Inc.	HIV pre-immunization and immunotherapy
EP3487507A4	2016-07-21	2020-04-08	American Gene Technologies International, Inc.	Viral vectors for treating parkinson's disease
EP3565564A4 *	2017-01-09	2020-09-23	American Gene Technologies International Inc.	Hiv immunotherapy with no pre-immunization step
US11820999B2	2017-04-03	2023-11-21	American Gene Technologies International Inc.	Compositions and methods for treating phenylketonuria
WO2019191314A1 *	2018-03-27	2019-10-03	American Gene Technologies International Inc.	Methods of manufacturing genetically-modified lymphocytes
CN112105731A	2018-03-30	2020-12-18	日内瓦大学	micro-RNA expression constructs and uses thereof
JPW02020027094A1 *	2018-07-31	2021-09-16	サイアス株式会社	A method for producing a regenerated T cell population via iPS cells
US11352646B2	2018-11-05	2022-06-07	American Gene Technologies International Inc.	Vector system for expressing regulatory RNA
US20220211845A1 *	2019-05-08	2022-07-07	The Wistar Institute Of Anatomy And Biology	Dna encoded il-36 gamma as an adjuvant
CN112048523A *	2019-06-05	2020-12-08	南京艾德免疫治疗研究院有限公司	Method for preparing high-titer lentiviral vector by conventional centrifugation
IL296096A *	2020-03-03	2022-11-01	American Gene Tech Int Inc	On demand expression of exogenous factors in lymphocytes to treat hiv

Similar Documents

Publication	Publication Date	Title
IL284348A	2021-07-29	Hiv pre-immunization and immunotherapy
IL262095A	2018-11-29	Anti-pacap antibodies and uses thereof
AU365268S	2015-11-17	Pendant
AU363632S	2015-08-20	Pendant
EP3229838A4	2018-06-06	Anti-c10orf54 antibodies and uses thereof
EP3319631A4	2019-01-09	Hiv pre-immunization and immunotherapy
IL265689A	2019-05-30	Anti-il-33 antibodies and uses thereof
EP3413926A4	2019-10-09	Hiv vaccination and immunotherapy
IL267794A	2019-09-26	Hiv immunotherapy with no pre-immunization step
GB2553642B	2021-08-04	Jewelry item
EP3222625A4	2018-05-02	Metal complex and light-emitting element using same
PL3512537T3	2024-02-26	T-cell immunotherapy
IL266049A	2019-06-30	Anti-o1 antibodies and uses thereof
EP3496563A4	2020-02-12	Gemstone
IL266082A	2019-06-30	Anti-chikv antibodies and uses thereof
IL264417A	2019-02-28	Anti-o2 antibodies and uses thereof
EP3132923A4	2017-05-17	Long structural member and structural member complex using same
EP3329880A4	2019-01-23	Intraocularly-mounted object and intraocularly-inserted object holding member
IL267450A	2019-08-29	Antibodies against lif and uses thereof
EP3149039B8	2020-04-01	Anti-neurotensin antibodies and uses thereof
EP3121182A4	2017-10-25	Metal complex and light-emitting element using same
EP3233919A4	2018-07-25	Dicam-specific antibodies and uses thereof

PT3541596T	2021-06-14	Tool element and tool	
GB201508028D0	2015-06-24	Sandfalls and the like	
EP3122522A4	2017-11-29	Jewelry tool	

Priority And Related Applications

Applications Claiming Priority (4)

Application	Filing date	Title
US201662360185P	2016-07-08	
US201662385864P	2016-09-09	
US201662409270P	2016-10-17	
PCT/US2017/013019	2017-01-11	Hiv pre-immunization and immunotherapy

Concepts

machine-extracted

machine-extracted				◆ Download Filter table ▼
Name	Image	Sections	Count	Query match
■ immunization		title	1	0.000
■ immunization		title	1	0.000
■ immunotherapy		title	1	0.000
Show all concepts from the description section				

Data provided by IFI CLAIMS Patent Services

Send Feedback Privacy Policy Help About **Public Datasets** Terms